TW202448887A - 取代吡唑并嘧啶化合物及其醫藥用途 - Google Patents

取代吡唑并嘧啶化合物及其醫藥用途 Download PDF

Info

Publication number
TW202448887A
TW202448887A TW113106397A TW113106397A TW202448887A TW 202448887 A TW202448887 A TW 202448887A TW 113106397 A TW113106397 A TW 113106397A TW 113106397 A TW113106397 A TW 113106397A TW 202448887 A TW202448887 A TW 202448887A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
substituted
compound
disease
Prior art date
Application number
TW113106397A
Other languages
English (en)
Chinese (zh)
Inventor
大場雄介
足達馨
櫻井健太朗
佐藤晋平
Original Assignee
日商日本煙草產業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日本煙草產業股份有限公司 filed Critical 日商日本煙草產業股份有限公司
Publication of TW202448887A publication Critical patent/TW202448887A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW113106397A 2023-02-24 2024-02-22 取代吡唑并嘧啶化合物及其醫藥用途 TW202448887A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-027432 2023-02-24
JP2023027432 2023-02-24

Publications (1)

Publication Number Publication Date
TW202448887A true TW202448887A (zh) 2024-12-16

Family

ID=92501386

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113106397A TW202448887A (zh) 2023-02-24 2024-02-22 取代吡唑并嘧啶化合物及其醫藥用途

Country Status (11)

Country Link
EP (1) EP4671247A1 (enExample)
JP (2) JP7737490B2 (enExample)
KR (1) KR20250151389A (enExample)
CN (1) CN120752239A (enExample)
AR (1) AR131919A1 (enExample)
AU (1) AU2024226032A1 (enExample)
CO (1) CO2025011311A2 (enExample)
IL (1) IL322520A (enExample)
MX (1) MX2025009965A (enExample)
TW (1) TW202448887A (enExample)
WO (1) WO2024177127A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140708A1 (zh) * 2023-12-31 2025-07-03 杭州百新生物医药科技有限公司 吡唑并嘧啶类化合物及其医药用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3064498T3 (pl) * 2013-10-30 2020-03-31 Shanghai Hengrui Pharmaceutical Co. Ltd. Pirazolopirymidon lub pochodne pirolotriazonu, sposób ich otrzymywania i ich zastosowania farmaceutyczne
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
ES2930151T3 (es) * 2019-01-14 2022-12-07 Innate Tumor Immunity Inc Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
KR102865929B1 (ko) * 2019-01-14 2025-09-29 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
WO2021132577A1 (ja) * 2019-12-27 2021-07-01 日本たばこ産業株式会社 アシルスルファミド化合物及びその医薬用途
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors
JP2024513227A (ja) * 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Nek7阻害剤
US20240287079A1 (en) * 2021-08-31 2024-08-29 Japan Tobacco Inc. 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
WO2024048519A1 (ja) * 2022-08-29 2024-03-07 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途
AU2024255473A1 (en) * 2023-04-14 2025-10-16 Takeda Pharmaceutical Company Limited Pyrazolopyrimidine derivatives as inhibitors of nlrp3

Also Published As

Publication number Publication date
AU2024226032A1 (en) 2025-09-11
IL322520A (en) 2025-10-01
CO2025011311A2 (es) 2025-09-08
CN120752239A (zh) 2025-10-03
WO2024177127A1 (ja) 2024-08-29
JP7737490B2 (ja) 2025-09-10
AR131919A1 (es) 2025-05-14
KR20250151389A (ko) 2025-10-21
MX2025009965A (es) 2025-09-02
JP2024120882A (ja) 2024-09-05
EP4671247A1 (en) 2025-12-31
JP2025176085A (ja) 2025-12-03

Similar Documents

Publication Publication Date Title
JP7483810B2 (ja) 6-アミノピラゾロピリミジン化合物及びその医薬用途
JP7585409B2 (ja) ピラゾロピリミジン化合物及びその医薬用途
CN112778331B (zh) 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
JP7737490B2 (ja) 置換ピラゾロピリミジン化合物及びその医薬用途
CN115867284A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
TW201819380A (zh) 作為抗病毒劑之稠合四環吡啶酮化合物
CN116322696A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
JP2024544553A (ja) ミエロイド細胞に発現するトリガー受容体2アゴニストとしての複素環化合物及び使用方法
JP7729000B2 (ja) 6-アルコキシピラゾロピリミジン化合物及びその医薬用途
JP2024544552A (ja) ミエロイド細胞に発現するトリガー受容体2アゴニストとしてのヘテロ環化合物
WO2024233847A2 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CN117881682A (zh) 6-氨基吡唑并嘧啶化合物及其医药用途
HK40112889A (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
WO2024207945A1 (zh) 作为aak1抑制剂的氮杂环类化合物
WO2017090716A1 (ja) ピラゾール誘導体の結晶